glp 1 agonist contraindication AJOG Expert Review: Glucagon-like peptide-1 receptor use in pregnancy: a review https://ow.ly/PTC950UCtoK Benefits and Risks of GLP-1

Sources for Figure 218

### Competing Interest Statement ASK, AMM, MCG, JMD, CB, CL, SWB, DJL, PML, DRD, JMC, JPF, YL, ARS, DAT, DWP, SH, RBR, MSL, and DAG are employees and stockholders of Pfizer Inc

A reminder that their story doesnt start in Hollywood

The Trump administration's grand bargain with drugmakers isn't working out as planned.

However, further research is needed to fully understand how these therapies exert their effect on body weight and in the last section we cover open questions about the potential mechanisms of multiagonist drugs, and the understanding of how gutbrain communication can be leveraged to achieve sustained body weight loss without adverse effects.

The GLP1-RAs vs sodium-glucose cotransporter-2 (SGLT-2) inhibitors cohort included new users of GLP-1 RAs (n=83,464) or SGLT-2 inhibitors (n=78,366), and the GLP1-RAs vs dipeptidyl peptidase-4 (DPP-4) inhibitors cohort included new users of GLP-1 RAs (n=108,322) or DPP-4 inhibitors (n=55,411)